A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Immune checkpoints (PD-1, CTLA-4, TIM-3, LAG-3) are inhibitory receptors that restrain T cell activation, essential for preventing autoimmunity and immunopathology but exploited by tumors and chronic pathogens. Checkpoint blockade (anti-PD-1, anti-CTLA-4) reverses T cell exhaustion, allowing antitumor and antiviral immunity. T cell exhaustion is distinct from anergy: exhausted cells express multiple checkpoints and low cytokine production.
Map checkpoint signaling cascades and how they oppose costimulatory signals. Study the clinical efficacy and immune-related adverse events of checkpoint inhibitors.
Checkpoint blockade does not simply 'remove brakes'; it shifts the balance toward activation. Not all exhausted T cells respond to checkpoint blockade; some may require additional costimulation.
From your study of T cell activation, you know that T cells require two signals to become fully activated: antigen recognition through the TCR (signal 1) and costimulation through molecules like CD28 binding B7 on the antigen-presenting cell (signal 2). Immune checkpoints are the mirror image of costimulation — they are inhibitory receptors that deliver a "stop" signal to activated T cells. Just as costimulation ensures that T cells respond vigorously when needed, checkpoints ensure that T cells do not respond too vigorously or for too long. The immune system needs both an accelerator and a brake.
CTLA-4 and PD-1 are the two best-characterized checkpoint receptors, and they operate at different stages of the T cell response. CTLA-4 competes directly with CD28 for binding to B7 ligands on antigen-presenting cells, but binds with much higher affinity. When CTLA-4 outcompetes CD28, the costimulatory signal is blocked and the T cell's activation is dampened. This primarily affects early T cell activation in lymph nodes. PD-1, by contrast, acts later — in the peripheral tissues where T cells encounter their targets. When PD-1 binds its ligands PD-L1 or PD-L2 (expressed on many cell types, including tumor cells), it recruits phosphatases that directly counteract TCR signaling, reducing T cell proliferation, cytokine production, and killing capacity.
T cell exhaustion is a distinct state that develops during prolonged antigen exposure — chronic viral infections or growing tumors that the immune system cannot clear. Exhausted T cells are not dead or deleted; they are alive and antigen-specific but functionally impaired. They progressively upregulate multiple checkpoint receptors (PD-1, TIM-3, LAG-3, TIGIT), lose the ability to produce effector cytokines, and exhibit reduced proliferative capacity. Exhaustion is not the same as anergy (which results from TCR signaling without costimulation) — exhausted cells were once fully activated but became progressively dysfunctional under sustained stimulation. Importantly, exhaustion is a spectrum: mildly exhausted cells retain some function and can be reinvigorated, while terminally exhausted cells cannot.
This biology became clinically revolutionary with the development of checkpoint blockade immunotherapy. Antibodies that block PD-1 (nivolumab, pembrolizumab) or CTLA-4 (ipilimumab) can release exhausted T cells from inhibition, allowing them to resume attacking tumor cells. The results in some cancers have been dramatic — durable remissions in metastatic melanoma, lung cancer, and other malignancies that were previously untreatable. But checkpoint blockade is not simply "removing the brakes." By releasing immune inhibition, these therapies also increase the risk of immune-related adverse events — autoimmune attacks on normal tissues including the colon, liver, skin, and endocrine glands. These side effects are a direct and predictable consequence of the biology: checkpoints exist to prevent exactly this kind of collateral damage, and blocking them removes protection from self-tissues as well as from tumors.